Although most studies indicate that the CNS is the key tissue upon which peripherally administered leptin initially acts to trigger its glucose-lowering effects in insulin-deficient diabetes, it remains unclear if the CNS pathways involved are the same as for centrally administered leptin44–48. This evidence concerns the gene LEP and diabetes mellitus.